ADYNOVATE Lyophilized Powder for solution
Antihemophilic Factor (Recombinant), PEGylated recombinant human FVIII
1000 IU
BAXALTA US Inc
| Pack size | 1 Glass Vial (5 ml) lyophilized antihemophilic factor (Recombinant) PEGylated + 1 Glass Vial (5 ml) solvent + 1 BAXJECT II Hi-Flow Needleless Transfer Device |
|---|---|
| Dispensing mode | POM |
| Source | USA |
| Agent | Modern Pharmaceutical Co. |
| Retail Price | 5535.50 AED |
Indications
ADYNOVATE Lyophilized Powder for solution is used for:
AMLODIPINE
For the treatment of hypertension and chronic stable angina
VALSARTAN
May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Losartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ace inhibitors
HYDROCHLOROTHIAZIDE
For the treatment of high blood pressure and management of edema
For the treatment of hypertension and chronic stable angina
VALSARTAN
May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Losartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ace inhibitors
HYDROCHLOROTHIAZIDE
For the treatment of high blood pressure and management of edema
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Antihemophilic Factor (Recombinant), PEGylated recombinant human FVIII :
Mechanism of Action
AMLODIPINE
Amlodipine decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through l-type calcium channels. Calcium ions entering the cell through these channels bind to calmodulin. Calcium-bound calmodulin then binds to and activates myosin light chain kinase (mlck). Activated mlck catalyzes the phosphorylation of the regulatory light chain subunit of myosin, a key step in muscle contraction. Signal amplification is achieved by calcium-induced calcium release from the sarcoplasmic reticulum through ryanodine receptors. Inhibition of the initial influx of calcium decreases the contractile activity of arterial smooth muscle cells and results in vasodilation. The vasodilatory effects of amlodipine result in an overall decrease in blood pressure. Amlodipine is a long-acting ccb that may be used to treat mild to moderate essential hypertension and exertion-related angina (chronic stable angina). Another possible mechanism is that amlodipine inhibits vascular smooth muscle carbonic anhydrase i activity causing cellular ph increases which may be involved in regulating intracelluar calcium influx through calcium channels
VALSARTAN
Valsartan is an arb that selectively inhibits the binding of angiotensin ii to at1, which is found in many tissues such as vascular smooth muscle and the adrenal glands. This effectively inhibits the at1-mediated vasoconstrictive and aldosterone-secreting effects of angiotensin ii and results in a decrease in vascular resistance and blood pressure. Valsartan is selective for at1 and has virtually no affinity for at2. Inhibition of aldosterone secretion may inhibit sodium and water reabsorption in the kidneys while decreasing potassium excretion. The primary metabolite of valsartan, valeryl 4-hydroxy valsartan, has no pharmacological activity
HYDROCHLOROTHIAZIDE
Hydrochlorothiazide, a thiazide diuretic, inhibits water reabsorption in the nephron by inhibiting the sodium-chloride symporter (slc12a3) in the distal convoluted tubule, which is responsible for 5% of total sodium reabsorption. Normally, the sodium-chloride symporter transports sodium and chloride from the lumen into the epithelial cell lining the distal convoluted tubule. The energy for this is provided by a sodium gradient established by sodium-potassium atpases on the basolateral membrane. Once sodium has entered the cell, it is transported out into the basolateral interstitium via the sodium-potassium atpase, causing an increase in the osmolarity of the interstitium, thereby establishing an osmotic gradient for water reabsorption. By blocking the sodium-chloride symporter, hydrochlorothiazide effectively reduces the osmotic gradient and water reabsorption throughout the nephron
Amlodipine decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through l-type calcium channels. Calcium ions entering the cell through these channels bind to calmodulin. Calcium-bound calmodulin then binds to and activates myosin light chain kinase (mlck). Activated mlck catalyzes the phosphorylation of the regulatory light chain subunit of myosin, a key step in muscle contraction. Signal amplification is achieved by calcium-induced calcium release from the sarcoplasmic reticulum through ryanodine receptors. Inhibition of the initial influx of calcium decreases the contractile activity of arterial smooth muscle cells and results in vasodilation. The vasodilatory effects of amlodipine result in an overall decrease in blood pressure. Amlodipine is a long-acting ccb that may be used to treat mild to moderate essential hypertension and exertion-related angina (chronic stable angina). Another possible mechanism is that amlodipine inhibits vascular smooth muscle carbonic anhydrase i activity causing cellular ph increases which may be involved in regulating intracelluar calcium influx through calcium channels
VALSARTAN
Valsartan is an arb that selectively inhibits the binding of angiotensin ii to at1, which is found in many tissues such as vascular smooth muscle and the adrenal glands. This effectively inhibits the at1-mediated vasoconstrictive and aldosterone-secreting effects of angiotensin ii and results in a decrease in vascular resistance and blood pressure. Valsartan is selective for at1 and has virtually no affinity for at2. Inhibition of aldosterone secretion may inhibit sodium and water reabsorption in the kidneys while decreasing potassium excretion. The primary metabolite of valsartan, valeryl 4-hydroxy valsartan, has no pharmacological activity
HYDROCHLOROTHIAZIDE
Hydrochlorothiazide, a thiazide diuretic, inhibits water reabsorption in the nephron by inhibiting the sodium-chloride symporter (slc12a3) in the distal convoluted tubule, which is responsible for 5% of total sodium reabsorption. Normally, the sodium-chloride symporter transports sodium and chloride from the lumen into the epithelial cell lining the distal convoluted tubule. The energy for this is provided by a sodium gradient established by sodium-potassium atpases on the basolateral membrane. Once sodium has entered the cell, it is transported out into the basolateral interstitium via the sodium-potassium atpase, causing an increase in the osmolarity of the interstitium, thereby establishing an osmotic gradient for water reabsorption. By blocking the sodium-chloride symporter, hydrochlorothiazide effectively reduces the osmotic gradient and water reabsorption throughout the nephron
Note
ADYNOVATE 1000 IU Lyophilized Powder for solution manufactured by BAXALTA US Inc. Its generic name is Antihemophilic Factor (Recombinant), PEGylated recombinant human FVIII. ADYNOVATE is availble in United Arab Emirates.
Farmaco UAE drug index information on ADYNOVATE Lyophilized Powder for solution is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.